Trial Profile

MTX-463-I101: A Phase 1 Randomized, Double-Blind, Dose-Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of MTX-463 in Healthy Adults

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MTX-463 (Primary)
Indications Fibrosis
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
Sponsors Mediar Therapeutics

Most Recent Events

22 Jan 2025 Last checked against ClinicalTrials.gov: US National Institutes of Health
10 Jan 2025 Status changed from recruiting to completed, according to a Mediar Therapeutics media release.
07 Aug 2024 According to a Mediar Therapeutics media release, company reports continued progress in US Phase 1 study of MTX-463, with approximately three quarters of the cohorts dosed, and completion of the trial expected by the end of 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com